Clarivate Epidemiology’s coverage of growth hormone deficiency comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France,…
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure (CHF) cases, but proven pharmacological treatment options are limited. In…
Clarivate Epidemiology’s coverage of overactive bladder (OAB) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Clarivate Epidemiology’s coverage of overactive bladder (OAB) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Because of the lack of disease-modifying agents for CKD, treatment is aimed at minimizing the symptoms and complications arising from progressively diminished kidney function and treating the cause…
Clarivate Epidemiology’s coverage of ovarian cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of renal…
Clarivate Epidemiology’s coverage of chronic fatigue syndrome (CFS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of chronic fatigue syndrome (CFS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…